Iovance Biotherapeutics shares gained over 5% pre-market after reporting encouraging early results for its lifileucel therapy in soft tissue sarcoma. Half of the evaluated patients showed tumour response, supporting a potential speedy approval pathway. Additionally, the company reported strong fourth-quarter earnings, driven by $65 million in revenue from Amtagvi.